Oncogenic Mutations of PIK3CA in Human Cancers
- 10 June 2010
- book chapter
- Published by Springer Nature
- Vol. 347, 21-41
- https://doi.org/10.1007/82_2010_68
Abstract
The involvement of the PIK3CA gene product p110α, the catalytic subunit of phosphatidylinositol 3-kinase (PI3K), in human cancer has been suggested for over 15 years, and support for this proposal had been provided by both genetic and functional studies, including most recently the discovery of common activating missense mutations of PIK3CA in a wide variety of common human tumor types. This chapter will focus on the discovery of these mutations and describes their relevance to a wide range of common human tumor types. Of note, the identification and functional analysis of the PIK3CA gene are reviewed in other chapters in this book. However, a brief mention will be made here of its general properties as background to our focus on the discovery of its cancer-specific mutations.Keywords
This publication has 138 references indexed in Scilit:
- Molecular alterations of EGFR and PIK3CA in uterine serous carcinomaGynecologic Oncology, 2009
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- Novel mutant‐enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancerInternational Journal of Cancer, 2007
- A transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature, 2007
- Mutations of the PIK3CA gene in hereditary colorectal cancersInternational Journal of Cancer, 2007
- Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activityProceedings of the National Academy of Sciences, 2007
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- RAF/RAS oncogenes and mismatch-repair statusNature, 2002
- Mutations of the BRAF gene in human cancerNature, 2002
- Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancersNature Genetics, 1997